KP1019 (FFC14A) from bench to bedside: Preclinical and early clinical development - An overview

M. A. Jakupec; V. B. Arion; S. Kapitza; E. Reisner; A. Eichinger; M. Pongratz; B. Marian; N. Graf v. Keyserlingk; Bernhard K. Keppler

doi:10.5414/CPP43595

KP1019 (FFC14A) from bench to bedside: Preclinical and early clinical development - An overview

M. A. Jakupec, V. B. Arion, S. Kapitza, E. Reisner, A. Eichinger, M. Pongratz, B. Marian, N. Graf v. Keyserlingk, Bernhard K. Keppler

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	595-596
Number of pages	1
Journal	International Journal of Clinical Pharmacology and Therapeutics
Volume	43
Issue number	12
DOIs	https://doi.org/10.5414/CPP43595
Publication status	Published - Dec 2005

Keywords

Redox activity
Ruthenium
Transferrin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.5414/CPP43595

Cite this

@article{df5d5d75c2884fdea380ce8f06c1d264,

title = "KP1019 (FFC14A) from bench to bedside: Preclinical and early clinical development - An overview",

keywords = "Redox activity, Ruthenium, Transferrin",

author = "Jakupec, {M. A.} and Arion, {V. B.} and S. Kapitza and E. Reisner and A. Eichinger and M. Pongratz and B. Marian and {Graf v. Keyserlingk}, N. and Keppler, {Bernhard K.}",

note = "CAN 145:116811 1-6 Pharmacology Institute of Inorganic Chemistry - Bioinorganic, Environmental and Radiochemistry,University of Vienna,Vienna,Austria. Journal 124875-20-3 (KP1019) Role: DMA (Drug mechanism of action), PAC (Pharmacological activity), THU (Therapeutic use), BIOL (Biological study), USES (Uses) (KP1019 is capable of occupying iron-binding sites of transferrin)",

year = "2005",

month = dec,

doi = "10.5414/CPP43595",

language = "English",

volume = "43",

pages = "595--596",

journal = "International Journal of Clinical Pharmacology and Therapeutics",

issn = "0946-1965",

publisher = "Dustri-Verlag Dr. Karl Feistle",

number = "12",

}

TY - JOUR

T1 - KP1019 (FFC14A) from bench to bedside: Preclinical and early clinical development - An overview

AU - Jakupec, M. A.

AU - Arion, V. B.

AU - Kapitza, S.

AU - Reisner, E.

AU - Eichinger, A.

AU - Pongratz, M.

AU - Marian, B.

AU - Graf v. Keyserlingk, N.

AU - Keppler, Bernhard K.

N1 - CAN 145:116811 1-6 Pharmacology Institute of Inorganic Chemistry - Bioinorganic, Environmental and Radiochemistry,University of Vienna,Vienna,Austria. Journal 124875-20-3 (KP1019) Role: DMA (Drug mechanism of action), PAC (Pharmacological activity), THU (Therapeutic use), BIOL (Biological study), USES (Uses) (KP1019 is capable of occupying iron-binding sites of transferrin)

PY - 2005/12

Y1 - 2005/12

KW - Redox activity

KW - Ruthenium

KW - Transferrin

U2 - 10.5414/CPP43595

DO - 10.5414/CPP43595

M3 - Article

SN - 0946-1965

VL - 43

SP - 595

EP - 596

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

IS - 12

ER -